37 results about "Plasmalogen" patented technology

The invention provides novel, simple, reliable and effective methods for separating various lipids from biological samples. In certain embodiments, the invention provides HILIC-based UHPLC separation methods. In one embodiment, the methods of the invention offer an efficient and rapid separation of ether glycophospholipids (e.g., plasmalogens) from their diacyl or monoacyl counterparts within the same lipid class. In certain instances, the invention relates to the use of a Waters ACQUITY UPLC® system.

Disclosed is a process for producing sphingomyelin and plasmalogen-form glycerophospholipid, which comprises the step (A) of extracting a total lipids from a chicken skin powder and drying the extract, the step (B) of subjecting the dried total lipids obtained in said step (A), to extraction treatment with a solvent mixture of an aliphatic hydrocarbon solvent and a water-soluble ketone solvent to separate an insoluble portion composed mainly of sphingomyelin and a soluble portion, the step (C) subjecting the insoluble portion composed mainly of sphingomyelin, obtained in said step (B), to extraction treatment with a solvent mixture of water and a water-soluble ketone solvent to remove a non-lipid component contained in the soluble portion, and the step (D) of drying the soluble portion obtained in said step (B), and subjecting the thus-obtained dried product to extraction treatment with a water-soluble ketone solvent to separate and recover an insoluble portion composed mainly of plasmalogen-form giycerophospholiuld.

According to the above production process, high-purity sphingomyelin, in particular, human-form sphingomyelin and plasmalogen-form sphingomyelin can be produced from chicken skin at high yields with simple procedures.

The present invention relates to a surfactant moryoupe and the preparation method and the application of the surfactant, which pertains to the technical field of pharmaceutical industry. The composition is made by extraction, purification and other steps of the tissues of bivalves mollusks, the composition contains rich phospholipid complex of the seafood which is composed of polyunsaturated fatty acids, wherein, the composition includes plasmalogen, active short-chain peptides and amino acids etc. The composition of the present invention has the surface activity of the surfactant, which can be used for preparing the drugs for replacement, therapy during the lack of pulmonary surfactants; furthermore, the invention has no immunogenicity.

This invention provides a process for producing a high-purity sphingomyelin and a high-purity plasmalogen-form glycerophospholipid from a biological material by simple procedures at high yields. The process comprises the steps of: (A) subjecting dried total lipids extracted from a biological material to extraction treatment with a specific mixture solution to separate an insoluble portion composed mainly of sphingomyelin and a soluble portion; (B) subjecting the insoluble portion, obtained in said Step (A), to washing treatment with a specific mixture solution to obtain crude sphingomyelin; (C) subjecting the soluble portion, obtained in said Step (A), to washing treatment with a water-soluble ketone solvent to obtain crude plasmalogen-form glycerophospholipid; (D) causing an enzyme to act on the crude sphingomyelin, obtained in said Step (B), to obtain sphingomyelin having a purity of 90% or more; and (E) causing an enzyme to act on the crude plasmalogen-form glycerophospholipid, obtained in said Step (C), to obtain plasmalogen-form glycerophospholipid having a purity of 40% or more.

The present invention relates generally to compounds such as alkylglycerol and alkoxyglycerol for use in increasing the endogenous level of plasmalogens in a mammal. In particular, these compounds are used for increasing the endogenous plasmalogen level to a level greater than the level in healthy mammals. According to the present invention such compounds are also for use in the prevention or treatment of diseases caused or affected by a decreased endogenous level of plasmalogens. A method for the manufacture of a dietary precursor for the use of the present invention is also part of the present disclosure.

A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention.

[PROBLEM TO BE SOLVED] To provide a method for producing ether phospholipids of high purity by an easy process. [SOLUTION] This production method comprises: (A) a step of extracting total lipids from organisms with non-polar organic solvent and branched alcohol mixture; and (B) a step of reacting the total lipids obtained by the step (A) with phospholipase A1 to decompose mixed diacyl-glycerophospholipids. This makes it possible to produce plasmalogen-type glycerophospholipids or ether phospholipids of high purity by an easy process.

The invention provides a production method for preparing a substance taking plasmalogen as an effective ingredient and being used for treating cranial nerve diseases from biological materials.The production method comprises the processes that 1, the biological materials are extracted through mixed solvent of aliphatic hydrocarbon solvent and water-soluble ketone solvent; 2, an insoluble part obtained in the process 1 is washed with the mixed solvent of the aliphatic hydrocarbon solvent and the water-soluble ketone solvent to obtain crude plasmalogen; 3, a soluble part obtained in the process 1 is treated to obtain crude plasmalogen; 4, a glycerol phosphatide hydrolase-phospholipase acts with the crude plasmalogen obtained in the process 2 to obtain the plasmalogen; 5, the glycerol phosphatide hydrolase-phospholipase acts with the crude plasmalogen obtained in the process 3 to obtain the plasmalogen.The purity of the effective ingredient plasmalogen of the medicine prepared through the method is high, and the plasmalogen is an ingredient contained in biological tissue, so that the preparation safety is very high.

The invention provides methods for increasing endogenous plasmalogen levels in an animal by administering to the animal an endogenous plasmalogen level increasing amount of one or more long chain polyunsaturated fatty acids (LCPUFAs).

The invention discloses application of microorganism-derived plasmalogen to treatment of colon cancer, and belongs to the technical field of biological medicines and microorganisms, and aims to provide a method for improving the colon cancer. The invention provides application of microorganism-derived plasmalogen to preparation of a drug for treating colon cancer. The microorganism-derived plasmalogen is extracted from any one or more of anaerobic microbes such as lactobacillaceae, bifidobacterium, clostridium butyricum and peptostreptococcus kluyver and van niel in a mixed manner. The microorganism-derived plasmalogen can reduce the expression of colon cancer related cytokines from a molecular level, and inhibit proliferation of colon cancer cells and reduce the number and volume of colonic adenomas of a colon cancer patient, can be used as an effective nutrition strategy for preventing and treating the colon cancer, and provides a theoretical support for efficient utilization of the enteric microorganism-derived plasmalogen.

The invention belongs to the medical field, providing an acetal phosphatide dyeing reagent group for a bone marrow smear and an application method thereof, wherein the reagent group using HgCl2 as the fixture and the Schiff reagent as the dyeing solution includes following reagents: the HgCl2 solution, the Schiff reagent, the sulfite water solution and the Mayer brazilein solution; the steps of the application method are as follows: (1) the bone marrow smear is fixed by the HgCl2; (2)the bone marrow smear is washed by distilled water; (3) the bone marrow smear is dyed by the Schiff reagent and washed by the sulfite water solution; (4) the bone marrow smear is dyed again by the Mayer brazilein solution and washed by flowing water; (5) the judgment of the dyeing result is as follows: cytolymph which is red is positive, and cytolymph which is not dyed is negative. The dyeing method of the invention has the advantages of easy realization, convenient observation of the dyeing result and extremely high specificity, and is an effective method for judging megakaryocytes in the acute leukemia M7 and other leukemia cells.

The invention belongs to the technical field of active substance screening, and relates to a preparation method and application of EPA/ARA type acetal phospholipid. The method comprises steps: continuously hydrolyzing a phospholipid complex by using PLA1 enzyme, and then extracting the EPA/ARA type acetal phospholipid from the enzymolyzed phospholipid by using a supercritical CO2 fluid extractiontechnology. The EPA/ARA type acetal phospholipid prepared by the invention has the advantages that the purity is 80% or more, compared with EPA type acetal phospholipids or ARA type acetal phospholipids, the EPA/ARA type acetal phospholipid has the advantages that the behavior cognition function of mice with the Alzheimer's disease is remarkably reduced, brain A beta aggregation and Tau protein aggregation are improved, and the EPA/ARA type acetal phospholipid can be used for preparing medicine for preventing and treating the Alzheimer's disease and other diseases and has wide market application prospects.

The invention belongs to a novel application of acetal phosphatidyl ethanolamine, and particularly relates to an application of acetal phosphatidyl ethanolamine in preparation of a product for reducing trimethylamine oxide in vivo. EPA acetal phosphatidyl ethanolamine is included. Experiments prove that the plasmalogen can effectively regulate the specific intestinal flora for converting choline into TMA and remarkably reduce the TMA and TMAO levels in vivo, the effect of the plasmalogen in reducing trimethylamine oxide in vivo is verified, and a new way is provided for reducing the level of trimethylamine oxide in vivo.

A method for preparing ¹³C labeled plasmalogens as represented by Formula B: —The method involves producing a ¹³C labeled cyclic plasmalogen precursor of Formula A, and conversion of the precursor to a plasmalogen of Formula B. These plasmalogens may potentially be useful in the determination of both the mechanism of action as well as the fate of plasmalogens in the body.